is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112. 

Current Cases

TransEnterix, Inc. [NYSE: TRXC]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against TransEnterix, Inc.

Oklahoma City, OK (June 13, 2016) – On June 2, 2016, a securities class action lawsuit was filed in the United States District Court for the Eastern District of North Carolina against TransEnterix, Inc. (NYSE: TRXC).  The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 10, 2016 through May 10, 2016.  More specifically, this litigation was filed because the Company failed to disclose deficiencies within TransEnterix’s 510(k) submission regarding SurgiBot that undermined the likelihood that SurgiBot would receive FDA clearance, which would leave the Company unable to commercialize the SurgiBot in 2016.

On May 10, 2016, the Company issued a press release relating to SurgiBot stating that it “expects to have further discussion with the FDA, but currently believes that a new 510(k) submission would be required to obtain clearance.”  The Company also stated that it decided to reprioritize its near-term regulatory efforts to focus on another submission.  As a result, the Company has taken actions to reduce headcount and investment related to the SurgiBot. On this news, TransEnterix common stock fell to close at $1.84 per share on May 11, 2016.

To join this class action, click InvestCertTRXC.pdf to obtain an investor certification. Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN:  Robin.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.